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Tumor necrosis factor (TNF) is of special significance 
among cytokines since its biological characteristics and 
functions are extremely varied. Multiple stu dies have proved 
that TNF can both inhibit the development of some kinds 
of new-growths and physiologically re gulate growth, dif-
ferentiation and metabolism of va rious cell types. A lot of 
research has been done into the connection between TNF 
and individual manifestations of lymphoid neoplasm [1–
4], as well as its prognostic validity in chronic lymphocy tic 
leukemia (CLL) [5, 6] and malignant lymphomas [7, 8]. 
However, the number of works on changes in TNF con-
centration in case of acute leukemia (AL) is insufficient and 
their results are often contradictory [9–14].
The aim of this research is to study TNF concentra-
tion in blood plasma of patients with AL, its production 
by the primary culture of peripheral blood mononuclear 
cells (PBMC) (mixture of blasts and lymphocytes) and to 
estimate the relation between these rates and some clini-
cal symptoms of the disease.
PATIENTS AND METHODS
The study includes 44 patients with AL (28 male 
and 16 female) from 16 to 81 years old (the median val-
ue is 57,5 years), 30 of them were diagnosed with AL for 
the first time, 14 were examined during first early relapse 
of the disease. On the basis of cytological, cytochemical 
and immunological analysis, 23 patients were diagnosed 
with acute lymphoblastic leukemia (ALL) and 21 patients 
were diagnosed with acute myeloid leukemia (AML). 
The TNF concentration was determined with the bio-
logical method [15] in blood plasma of patients with AL 
as well as in conditioned substrates of PBMC cultures.
The TNF concentration was examined for patients 
without infectious complications, before the beginning 
of cytostatic treatment, in blood plasma and superna-
tant fluid of the cultures of mononuclear cells obtained 
from peripheral blood in the density gradient of ficoll-
verografin (ρ = 1.077). PBMC of the patients conta-
ining blast cells and lymphocytes were cultivated for cy-
tokine production in the concentration of 5•105 cells/ml 
of substrate RPMI-1640 in the atmosphere of СО2 with 
the temperature of 37 °С during 24 hours without stimu-
lation. The plasma and supernatants before the study 
were kept under the temperature conditions of –30 °С.
The TNF concentration (total α + β) was deter-
mined using the biological method based on the lysis 
level of TNF-sensitive culture of transformed mouse fi-
broblasts of L929 line. The experiment used trypsini-
zed L929 line cells on the 3rd day after passage, marked 
by the standard method with Н3-methyl thymidine 
and processed with actinomycin D. The suspension of 
the marked L929 line cells in 8•105 cells/ml concen-
tration of the substrate was introduced by 100 µl into 
a 96-well plate; 150 µl of the test samples of plasma or 
supernatants of PBMC cultures were added into every 
well; the study was done in triplets. The cytotoxic ef-
fect of TNF from the test samples on the L929 line cells 
was estimated by the level of spontaneous appearance 
of the radioactive tracer after 24 hours of incubation by 
the radiometric method. A calibration curve based on 
the results of recombinant human TNF titration (Sig-
ma, LD50 = 0.067 ng/ml) on the L929 line cells was used 
to determine the TNF concentration.
Taking into account the possibility of TNF presence 
in blood not only from immunocompetent cells and leu-
kemic cells of peripheral blood, a ratio of TNF produc-
tion by PBMC to its concentration in blood plasma was 
calculated too (index I).
The control group for determining normal indica-
tors of TNF concentration in blood and its production 
by PBMC consisted of 15 healthy persons, blood do-
nors, from 21 to 39 years old, 11 of them being male and 
4 female.
Statistical summarizing of obtained data has been 
performed using application programs Statistica 6.0 and 
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MS Excel with program maintenance Attestat. Para-
metrical criteria (the mean and its standard error) were 
used after proving normal (Gaussian) distribution of 
the data applying Epps — Pally test. The difference 
among the compared groups using t-test was considered 
to be significant if the error probability was < 5%. Pear-
son’s correlation coefficient (r) was applied for correla-
tion analysis.
RESULTS AND DISCUSSION
Values of TNF concentration in blood plasma of 
patients with AL depending on demographic indica-
tors and some hematological parameters are  presented 
in the Table. In the general group of patients with AL, 
TNF concentration in blood plasma was on  average 
0.971 ± 0.136 ng/ml, which is more than 10 times 
as much as that in the group of healthy individu-
als (0.089 ± 0.017 ng/ml; p < 0.001). TNF concentra-
tion in blood plasma did not depend on the AL vari-
ant: TNF in the plasma of the patients with ALL was 
1.065 ± 0.242 ng/ml, while that of the patients with AML 
was 0.908 ± 0.163 ng/ml (p > 0.05).
Table
Concentration of TNF in blood plasma of patients with AL and its 
production by PBMC depending on age, sex and hematological 
parameters (М ± m)
Indicant TNF, ng/ml TNF of PBMC, ng/ml Index (I)**
Control group 0.089 ± 0.017 0.070 ± 0.002 0.768 ± 0.046
Patients with AL
ALL
AML
0.971 ± 0.136* 0.292 ± 0.072* 0.379 ± 0.080*
1.065 ± 0.142 0.360 ± 0.030 0.605 ± 0.116
0.908 ± 0.163 0.219 ± 0.056* 0.232 ± 0.063*
Age, years:
< 60
> 60
1.016 ± 0.164 0.306 ± 0.100 0.389 ± 0.101
0.893 ± 0.148 0.258 ± 0.066 0.356 ± 0.135
Sex:
male
female
0.882 ± 0.165 0.273 ± 0.099 0.435 ± 0.116
1.104 ± 0.137 0.330 ± 0.092 0.290 ± 0.096
Blast cells in bone marrow, %:
< 75
> 75
0.980 ± 0.178 0.200 ± 0.040 0.326 ± 0.086
0.953 ± 0.111 0.497 ± 0.110* 0.489 ± 0.172
Hemoglobin, g/l:
> 100
< 100
0.721 ± 0.233 0.176 ± 0.061 0.356 ± 0.223
1.033 ± 0.149 0.349 ± 0.103 0.385 ± 0.085
Erythrocytes, ×1012/l:
> 3 0.858 ± 0.172 0.166 ± 0.053 0.303 ± 0.128
< 3 1.027 ± 0.156 0.370 ± 0.101* 0.409 ± 0.092
Platelets, ×109/l:
> 100 0.930 ± 0.174 0.203 ± 0.048 0.360 ± 0.123
< 100 1.053 ± 0.189 0.430 ± 0.104* 0.411 ± 0.114
Leukocytes, ×109/l:
< 4
4–9
> 9
0.796 ± 0.153 0.456 ± 0.197 0.534 ± 0.133
1.090 ± 0.129 0.423 ± 0.120 0.365 ± 0.143
0.940 ± 0.195 0.193 ± 0.045* 0.358 ± 0.104
Erythrocytes sedimentation rate, mm/h:
< 20 0.772 ± 0.189 0.125 ± 0.057 0.418 ± 0.134
> 20 1.031 ± 0.155 0.328 ± 0.086* 0.368 ± 0.083
*p < 0.05 — statistical significance of differences compared to the figures 
of the previous group.
**Ratio of TNF production by PBMC to its concentration in blood plasma.
TNF concentration in blood plasma in age and gen-
der groups of patients with AL in statistical terms was 
signifi cantly higher (p < 0.001) than the corresponding 
value in the control group; however it showed no depen-
dence on the age and sex of patients.
TNF concentration in plasma did not depend on 
degree of leukemic infiltration in bone marrow. TNF 
concentration in AL patients with more significant 
(> 75% blasts) bone marrow infiltration was an  average 
0.953 ± 0.211 ng/ml and did not differ from corres-
ponding value in patients with lower amount of blasts 
(< 75%) in bone marrow (0.980 ± 0.178 ng/ml; p >0.05).
To determine the relation between TNF concentra-
tion in plasma and erythrocyte number in the patients’ 
peripheral blood, they were divided into two groups: 
those with erythrocyte level at least 3•1012/l and below 
3•1012/l. TNF concentration in blood plasma of patients 
with the erythrocyte number < 3•1012/l turned out to be 
more intense (1.027 ± 0.156 ng/ml) than that of patients with 
the number of erythrocytes > 3•1012/l (0.858 ± 0.172 ng/ml; 
p > 0.05). Patients with hemoglobin concentration < 100 g/l 
also manifested statistically unconfirmed high TNF con-
centration (1.033 ± 0.149 ng/ml) compared to the corre-
sponding indicator for patients whose hemoglobin level 
was > 100 g/l (0.721 ± 0.233 ng/ml).
No statistically significant difference was found be-
tween TNF concentration in blood plasma and number 
of platelets of patients with AL. The content of TNF in 
case of patients with thrombocytopenia (< 100•109/l) 
was 1.053 ± 0.189 ng/ml and was insignificantly higher 
than that in the group of patients with the normal num-
ber of platelets (0.930 ± 0.274 ng/ml).
Depending on the number of leukocytes in the pe-
ripheral blood, the patients were divided into the group 
with leukopenia (number of leukocytes < 4•109/l), group 
with the normal number of leukocytes and group of those 
with leukocytosis (number of leukocytes > 9•109/l). TNF 
concentration in blood plasma was the lowest in the group 
of patients with leukopenia, though it did not vary signi-
ficantly in different groups being equal to 0.796 ± 0.253, 
1.090 ± 0.229 and 0.940 ± 0.195 ng/ml, respectively.
In ALL patients, we established low grade direct cor-
relation between absolute blast cell number in periphe ral 
blood and TNF level (r = 0.34). The same correlation in 
AML had lower expression (r = 0.22).
TNF concentration in the blood plasma of the pa-
tients with raised (> 20 mm/h) erythrocyte sedimenta-
tion rate is somewhat higher (1.031 ± 0.155 ng/ml), than 
that of the patients with the normal erythrocyte sedi-
mentation rate.
In the general group of patients with AL, TNF pro-
duction by PBMC was four times (p < 0.01) as high as 
the corresponding estimate in the control group and 
reached 0.292 ± 0.072 ng/ml. The index of ratio be-
tween the TNF concentration produced in PBMC cul-
ture and its content in peripheral blood (Index I) of the 
patients amounted to 0.379 ± 0.080, which is less than 
that of healthy individuals — 0.786 ± 0.046 (p < 0.001). 
PBMC of patients with ALL produce more TNF 
(0.360 ±0.130 ng/ml) than that of patients with AML 
(0.219 ± 0.056 ng/ml; p < 0.05). The index of TNF pro-
duction was also significantly higher in patients with ALL. 
Thus, the ratio of TNF production by PBMC to its con-
centration in the plasma of patients with ALL amounted 
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to 0.605 ± 0.160 and significantly differed from the rate 
of patients with AML (0.232 ± 0.063; p < 0.05).
TNF production by PBMC for patients with AL did 
not depend on their age and sex. Similarly, the relation 
between TNF production by PBMC and its concentra-
tion in blood plasma (Index I) in age and gender groups 
did not differ significantly.
On the other hand, TNF production by PBMC in case 
of AL patients with more significant bone marrow infil-
tration (> 75% blasts) was approximately 2.5 times as high 
as corresponding estimate in patients with lower (< 75%) 
percent of blasts in bone marrow (0.497 ± 0.110 ng/ml vs 
0.200 ± 0.040 ng/ml, respectively; р < 0.02). However, 
the fraction of TNF produced by PBMC in TNF con-
tent in plasma did not differ considerably between these 
groups of AL patients (see the Table).
TNF production by PBMC of the patients with low 
hemoglobin level was two times higher than that of pa-
tients without symptoms of anemia; however, the diffe-
rence is statistically negligible (see the Table). In case of 
patients with low number of erythrocytes (< 3•1012/l), 
TNF production by blood cells was statistically signi-
ficantly more intensive than that of the patients with 
the normal level of erythrocytes (0.370 ± 0.101 and 
0.166 ± 0.053 ng/ml, respectively; p < 0.05). The fact 
that patients had anemia did not have significant effect on 
the proportion between TNF production by PBMC and 
its content in blood plasma (Index I), which,  however, 
was lower than that in the control group.
Thrombocytopenia (< 100•109/l) in patients with 
AL was accompanied by twice as high a capability of 
MCBP to produce TNF (0.430 ± 0.104 ng/ml) as that 
of the patients with the platelet level of at least 100•109/l 
(0.203 ± 0.048 ng/ml; p < 0.05). In case of thrombocyto-
penia, the ratio of TNF production by PBMC to its con-
centration in blood plasma is somewhat higher. The index 
of proportion (I) in case of thrombocytopenia amounts 
to 0.411 ± 0.114, while for patients with the normal num-
ber of platelets it was 0.360 ± 0.123 (p > 0.05).
When the number of leukocytes was rising, TNF syn-
thesis by PBMC was appreciably decreasing. For pa-
tients whose leukocyte number was 4–9•109/l, this fi gure 
amounted to 0.423 ± 0.120 ng/ml, while in case of leuko-
cytosis > 9•109/l, it was statistically significantly lower than 
in the previous groups (0.193 ± 0.045 ng/ml; p < 0.05). 
Similarly, in these groups of patients most TNF produc-
tion rate by PBMC (Index I) was found in the blood plas-
ma of patients with leukopenia (0.534 ± 0.133 vs 0.365 ± 
0.143 and 0.358 ± 0.104, respectively), however, the dif-
ferences were statistically negligible.
In ALL, we observed low grade negative correlation 
between absolute blast cell number in peripheral blood 
and TNF production by PBMC (r = –0.27). That cor-
relation was characterized as middle grade positive in 
AML patients (r = 0.38).
Statistically significant changes in TNF produc-
tion of PBMC culture in patients with AL were found to 
be rela ted to the erythrocyte sedimentation rate which 
may bear some relation to tumor intoxication syn-
drome. In case of higher erythrocyte sedimentation rate 
(> 20 mm/h) PBMC synthesized more TNF (0.328 ± 
0.086 ng/ml) than in case of patients with erythrocyte 
sedimentation rate < 20 mm/h (0.125 ± 0.057 ng/ml; 
p < 0.05).  However, the indicators of TNF production 
in PBMC culture ratio to its concentration in plasma (I) 
did not change significantly depending on the erythro-
cyte  sedimentation rate.
TNF synthesis in PBMC culture of the patients 
whose clinical course of the disease was accompanied 
with symptoms of tumor intoxication (such as fever 
without signs of infection, unmotivated loss of weight, 
sweating and fatigue) was somewhat lower being equal 
to 0.195 ± 0.05 ng/ml, while in case of patients without 
clinical symptoms of intoxication TNF production by 
PBMC was equal to 0.346 ± 0.108 ng/ml (p > 0.05). In 
case of patients with intoxication caused by the disease, 
the relation of TNF production by PBMC to its concen-
tration in the plasma (I) was significantly (p<0.02) lower 
than that of patients without these symptoms.
The relation between the TNF concentration in blood 
plasma and TNF production by PBMC of patients with 
AL was subjected to correlation analysis. It was found out 
that the TNF concentration in blood plasma increased 
if TNF production in PBMC culture rose. A statistically 
significant (p < 0.05), average in its power, direct corre-
lative relation (r = 0.39; see the Figure) was established 
between these factors. Link between the values can be ex-
pressed in logarithmic equation of regression:
y = 0.118e0.119x
where: x — TNF production by PBMC in AL patients,
y — TNF concentration in blood plasma of AL patients.
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Figure. Relation between TNF concentration in blood plasma 
of patients with AL and TNF production by PBMC
Research into the role of TNF in patients with AL is 
mostly focused on children with ALL [11, 12]. Diffe rent 
authors point out the increase in TNF concentration of 
patients with AL; however, information on other cytokines 
is not so unambiguous [9, 10, 11, 13]. In this exami nation 
of adult individuals with AL, we have also found statisti-
cally significant increase in TNF concentration indepen-
dent of the patients’ age and sex. Like Potapnev et al. [11], 
we did not find any relation between TNF concentration 
and the number of blast cells in the bone marrow. But we 
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ascertain positive correlation of TNF level with blast cell 
number in peripheral blood, more distinct in ALL than in 
AML. The increased concentration of TNF in case of AL 
as well as in other lymphoid neoplasm determines concrete 
clinical symptoms of a pathological process — constitu-
tional symptoms, anemia and even depressive syndrome 
[10, 13, 14]. This research has also established a relation 
between TNF and anemia as well as leukopenia but these 
data were statistically negligible.
Research of the TNF production by PBMC can im-
prove the understanding of its pathogenic role in AL. It 
was found out that concentration of TNF and interleukin-
1β еx vivo is positively correlated to the number of mono-
cytes and concentration of intercellular TNF [16], which 
attests to the normal capacity of monocytes of patients 
with ALL to produce cytokines еx vivo. Potapnev et al. [11] 
and Mazitova [12] demonstrated that children with ALL 
initially preserve the capacity of lymphocytes to produce 
TNF. We observed a statistically significant raise of TNF 
production by PBMC in the adult patients. Its associa-
tion with the development of anemia, thrombocytopenia 
and percent of blast cells in bone marrow, corresponding-
ly, was also confirmed. These results prove that increase 
in TNF production plays a certain role in suppressing 
erythro- and thrombocytopoesis as leukemia prog resses. 
The relation between TNF and symptoms of intoxica-
tion was demonstrated when exami ning its production 
by PBMC. Apparently, cultivating PBMC we determine 
in supernanant not only the concentration of TNF pro-
duced by immune competent cells (rema ining monocytes, 
lymphocytes). The high level of TNF in PBMC culture 
of AL patients also attests to the fact that it is produced 
by tumor cells. The decrease of index (I) that partly re-
flects TNF produced by PBMC in the general level of 
TNF in blood plasma of patients bears out this theory as 
well. These data may be suggestive of the presence of ot-
her significant sour ces of TNF in AL patients.
Two main sources of high TNF production could be 
ascertain in AL: immune system as manifestation of com-
mon patients’ response on tumor and malignant (leuke-
mic) cells. Most likely, the first source prevails because 
TNF blood levels in ALL and AML practically do not 
differ. At the same time, ability of lymphoid and my-
eloid lineage blasts to produce TNF and its influence on 
a growth of the blast cells remarkably differ. TNF pro-
duction by lymphoblasts in ALL is quite higher, than its 
production by myeloid blasts in AML. These results of 
our study correspond to experimental data that mouse 
ALL cells of L1210 line are capable to constitutive ex-
pression of TNF mRNA and TNF secretion into me-
dium destroying blood vessels endothelium and corre-
lating with leukemia expansion rate [17]. In contrast to 
L1210 cells, in human AML cells of K526 line TNF genes 
are repressed, the cells do not express TNF mRNA and 
do not secrete the cytokine into medium. But K526 cells 
might obtain TNF by paracrine way from other cells  using 
specific receptors [18]. Our study shows, that TNF is in-
hibiting growth factor for lymphoblasts in ALL, what is 
proved by negative correlation between blast number and 
TNF production by PBMC. Such correlation is positive 
in AML and could indicate that the TNF stimulates of 
myeloid blasts proliferation.
Thus, increased TNF level in AL patients may be 
viewed as a proapoptotic manifestation of changes in 
hematopoiesis and as one of factors that contribute to 
the development of anemia and thrombocytopenia as 
well as possibly to intoxication symptoms.
CONCLUSIONS
1. TNF (α + β) concentration in blood plasma of pa-
tients with AL is significantly increased as results of pa-
tient’s immune system response on tumor and raised 
TNF production by leukemic cells.
2. TNF production by lymphoblasts in ALL is quite 
higher than its production by myeloid blasts in AML, 
and besides TNF could be considered inhibiting growth 
factor for lymphoblasts in ALL and it stimulate myeloid 
blasts proliferation in AML.
3. Increased TNF concentration in blood and raised 
TNF production by PBMC in AL patients are accom-
panied by higher number of blast cells in bone marrow 
and peripheral blood, anemia, thrombocytopenia and 
increase in erythrocyte sedimentation rate, what makes 
a possibility to use of TNF values as prognostic indi-
ces in AL.
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ФАКТОР НЕКРОЗА ОПУХОЛЕЙ 
ПРИ ОСТРОМ ЛЕЙКОЗЕ
С.В. Примак, В.Л. Матлан, В.А. Барилка, 
О.А. Шалай, В.Е. Логинский
Резюме. Цель: изучить уровень фактора некро-
за опухоли (ФНО) в плазме крови больных острым 
лейкозом (ОЛ), его продукцию в первичной культу-
ре мононуклеарных клеток периферической крови 
(МКПК) и выяснить связь между этими показате-
лями и гематологическими проявлениями ОЛ. Ма-
териал и методы: концентрацию ФНО исследовали 
в плазме крови 44 больных ОЛ биологическим мето-
дом, основанным на его цитолитическом эффекте 
в чувствительной к ФНО культуре трансформиро-
ванных мышиных фибробластов линии L929, опре-
деляемом радиометрическим методом. Результа-
ты: концентрация ФНО в плазме крови больных 
ОЛ существенно превышает нормальные значения, 
его продукция МКПК также возрастает. Анемия 
и тромбоцитопения сопровождаются повышением 
концентрации ФНО в плазме крови, как и его 
продукции МКПК. Выводы: результаты исследо-
вания позволяют расценивать повышенный уровень 
ФНО при ОЛ как проапоптотическую манифеста-
цию изменений гемопоэза, приводящую к развитию 
анемии и тромбоцитопении. 
Ключевые слова: фактор некроза опухолей, 
острый лейкоз, острый лимфобластный 
лейкоз, острый миелобластный лейкоз, 
анемия, тромбоцитопения.
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